IP Library Granted Patent US 11,612,580
Granted Patent B2
US 11,612,580 · App. 16/756,705 · Granted Mar 28, 2023

Compositions for inhibiting 3′ repair exonuclease 2 and methods of screening for such compositions

Inventors: Edward Paul Hasty (San Antonio, TX); Dmitri Nickolaevich Ivanov (San Antonio, TX)
Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
A61K31/24A61K31/136A61K31/192A61K31/352A61K31/405A61K31/53A61K31/655A61K49/0043C12N15/113C12Q1/6806C12Q2600/136
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,612,580
App. No.
16/756,705
Granted
Mar 28, 2023
Kind
B2
Abstract

Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.

Claims (12)

1. A method of identifying an agent that inhibits exonuclease activity of TREX2, said method comprising:

providing an oligonucleotide-based substrate with a reporter associated with 3′ end of the oligonucleotide-based substrate and a complementary quencher associated with 5′ end of the oligonucleotide-based substrate;

incubating the oligonucleotide-based substrate in the presence of TREX2 and a compound under reaction conditions for a sufficient period of time; and

determining amount of reporter disassociated from the oligonucleotide-based substrate, wherein an increase in the amount of reporter disassociated from the oligonucleotide-based substrate indicates that the compound is an agent that inhibits exonuclease activity of TREX2.

2. The method of claim 1 , wherein the oligonucleotide-based substrate is a single stranded deoxyribonucleic acid.

3. The method of claim 1 , wherein the oligonucleotide-based substrate is a 20 nucleotide-long single stranded deoxyribonucleic acid.

4. The method of claim 1 , wherein the reporter is covalently attached to the base of the second to last nucleotide on the 3′ end.

5. The method of claim 1 , wherein the reporter is located at 25 nucleotides or less from the complementary quencher.

6. The method of claim 1 , wherein the reporter is a fluorophore.

7. The method of claim 1 , wherein the reporter is Fluorescein.

8. The method of claim 7 , wherein the complementary quencher is 4′-(4-Nitro-phenyldiazo)-2′-methoxy-5′-methoxy-azobenzene-4″-(N-2-oxy ethyl (4,4′ dimethoxy trityl))-N-ethyl-2-cyanoethyl-(N,N-diisopropyl)-phosphoramidite.

9. The method of claim 1 , wherein the reporter is tetramethylrhodamine (TAMRA).

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 12, 2023
From: UNIVERSITY OF TEXAS HLTH SCI CTR AT SAN ANTONIO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064880/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2020
From: HASTY, EDWARD PAUL; IVANOV, DMITRI NICKOLAEVICH
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 053669/0096 →
Continuity (2)
Provisional Application 62572820 · Oct 16, 2017
Related Publication 20200253913A1 · Aug 13, 2020